CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-14 | MCKENZIE DIANA Director | Grant or award · Deferred Stock Units | +89.93 | $350.79 | $32K | 4,656.45 |
| 2023-06-15 | Arbuckle Stuart A EVP, COO | Exercise or conversion 10b5-1 | +8,603 | $187.53 | $1.6M | 65,159 |
| 2023-06-15 | Arbuckle Stuart A EVP, COO | Sale 10b5-1 | −8,603 | $349.00 | $3.0M | 56,556 |
| 2023-06-15 | Arbuckle Stuart A EVP, COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −8,603 | 8,603 | ||
| 2023-05-30 | Arbuckle Stuart A EVP, COO | Sale 10b5-1 | −82 | $329.82 | $27K | 56,556 |
| 2023-05-30 | Ambrose Kristen SVP & Chief Accounting Officer | Sale 10b5-1 | −289 | $329.82 | $95K | 6,838 |
| 2023-05-08 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −2,850 | $350.00 | $998K | 32,038 |
| 2023-05-08 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −1,125 | $349.00 | $393K | 35,387 |
| 2023-05-05 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −422 | $350.03 | $148K | 34,888 |
| 2023-05-05 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −708 | $349.38 | $247K | 36,683 |
| 2023-05-05 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −171 | $350.30 | $60K | 36,512 |
| 2023-05-03 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −2,053 | $350.44 | $719K | 36,038 |
| 2023-05-03 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −728 | $351.60 | $256K | 35,310 |
| 2023-05-03 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −2,008 | $349.22 | $701K | 39,891 |
| 2023-05-03 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −1,800 | $350.53 | $631K | 38,091 |
| 2023-05-03 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −700 | $351.59 | $246K | 37,391 |
| 2023-05-02 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −1,411 | $350.32 | $494K | 38,302 |
| 2023-05-02 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −42 | $351.65 | $15K | 38,260 |
| 2023-05-02 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −169 | $353.24 | $60K | 38,091 |
| 2023-05-02 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −4,645 | $349.48 | $1.6M | 43,704 |
Page 29 of 40 · 781 trades